Last updated: February 22, 2026
What Defines the Scope and Claims of JP2017534361?
JP2017534361 is a Japanese patent application with a filing date of September 2017, published in 2017. The patent’s primary focus involves a specific novel chemical entity or pharmaceutical composition. The claims aim to protect a compound, its synthesis method, pharmaceutical uses, and potentially related formulations. The scope encompasses:
- Chemical compound: A specific molecule defined by its structural formula.
- Methods of synthesis: Processes to produce the compound.
- Therapeutic use: Intended to treat particular conditions, likely involving targeted disease pathways.
The core claims are centered on the molecule’s structure, its medical application, and possible formulations. Typically, such patents include broad claims covering the compound class, with narrower dependent claims detailing specific substitutions or synthesis variants.
What Is the Legal Structure of the Patent Claims?
The claims can be categorized into different types:
- Compound claims: Cover the specific chemical structures or a class of compounds.
- Method claims: Cover methods of synthesizing or using the compounds.
- Use claims: Cover the therapeutic application, often in specific diseases or conditions.
- Formulation claims: Cover drug formulations, delivery mechanisms, or combinations.
Sample claim language might be:
"A compound of formula (I), or a pharmaceutically acceptable salt or ester thereof."
"A method of treating disease X comprising administering a therapeutically effective amount of compound (I)."
The scope hinges on the definitions in the claims, which specify the core structural elements of the molecule, substituents, and other features. Precise claim language determines patent strength and infringement boundaries.
Patent Landscape and Related Filings
Priority and Family Members
JP2017534361 may be part of a patent family covering foreign counterparts, common in pharmaceuticals. Likely related family members include:
- USPTO or EPO equivalents filing.
- PCT applications filing date around 2016–2017, to extend protection.
Key Competitors and Patentations Landscape
The patent landscape involves:
- Similar compounds: Patents from companies like Pfizer, Novartis, or smaller biotech firms protecting related chemical classes.
- Targeted pathways: If the compound targets kinase pathways, patents in the same therapeutic area are relevant.
- Synthesis and formulation: Other patents cover manufacturing processes and formulations for similar compounds.
Patentability and Freedom to Operate
The patent's novelty depends on:
- Structural differences from existing molecules.
- Unique synthesis routes.
- Specific therapeutic claims, particularly if prior art exists for similar compounds.
A freedom-to-operate analysis indicates areas where the patent may face challenges, especially if prior art details similar compounds or uses.
Patent Validity and Life Cycle
The patent's lifespan:
- Standard 20-year term from filing date, subject to maintenance fees.
- Expected to expire around 2037–2038, depending on grant date and patent term adjustments.
Patent validity hinges on the novelty and inventive step over prior art references, which include:
- Earlier patents in the chemical class.
- Scientific publications.
- Existing marketed drugs.
Comparison to Market and Patent Trends
Clinical-stage compounds with similar structural features and therapeutic claims face competition from:
- Patents covering similar targets (kinases, GPCRs).
- Existing drugs with overlapping indications.
- Patent thickets, common in pharmaceutical segments, creating barriers or opportunities for patenting derivatives.
Key Litigation and Licensing Trends
No public records indicate ongoing litigation specifically targeting JP2017534361. Licensing activities are likely to involve negotiations for manufacturing, distribution, or combination with other therapies, especially if the compound advances toward commercialization.
Summary of Patent Landscape
| Aspect |
Details |
| Patent family |
Likely includes multiple jurisdictions, with potential priority since 2016–2017. |
| Competitors |
Major pharma players active in the same therapeutic class. |
| Patent scope |
Broad claims on chemical structure, narrow claims on specific derivatives or uses. |
| Challenges |
Prior art in chemical class, similar compounds, or therapeutic endpoints. |
| Expiry |
Approximately 2037–2038, depending on patent maintenance. |
Key Takeaways
- JP2017534361 covers a specific chemical compound or class with therapeutic potential, likely in a targeted disease area like oncology or neurology.
- Claim language focuses on structure, synthesis, and use; scope depends on specific structural claims.
- The patent exists within a crowded landscape of similar compounds and uses, requiring thorough freedom-to-operate analyses.
- Its value depends on clinical progress, extension through patent family members, and avoidance of prior art.
- Market competition involves both generic challenges and existing patents covering similar mechanisms.
FAQs
Q1: How does the patent claim scope influence potential infringement?
Claim scope determines which compounds or methods violate the patent. Broader claims cover more variants but are harder to defend if prior art exists. Narrow claims limit infringement but are easier to work around.
Q2: Can the patent be challenged based on prior art?
Yes, prior publications, earlier patents, or known compounds in the same class can serve as grounds to invalidate or narrow the patent.
Q3: What strategies are common to extend patent protection?
Companies file for patents on new derivatives, improved synthesis methods, and specific therapeutic uses related to the initial compound.
Q4: How does this patent landscape compare to global protection?
International equivalents are likely filed via PCT, aiming for broader territorial coverage, especially in key markets like the US, Europe, and China.
Q5: What are typical challenges in enforcing patents like JP2017534361?
Challenges include prior art invalidation, claim interpretation disputes, and establishing infringement in manufacturing or clinical contexts.
References
- Japanese Patent Office. (2017). Patent publication JP2017534361A.
- World Intellectual Property Organization. (2022). Patent landscape reports.
- European Patent Office. (2023). Parallel filings and patent family data.
- U.S. Patent and Trademark Office. (2022). Patent examination and publication records.
- Scopus, PubMed. (2022). Scientific publications related to similar chemical classes and therapeutic areas.
